指南与共识妇科生殖医学

2023年国际循证指南:多囊卵巢综合征评估与管理的推荐意见

Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
指南 / 共识 · Fertil Steril · 2023-08-14

2023年国际循证指南更新基于既往证据、临床专业与患者偏好,针对多囊卵巢综合征的评估与管理提出254条推荐和实践要点。证据质量总体仍为低至中等,指南在诊断标准、代谢与心理特征识别、生活方式及生育管理等方面作出关键更新。

要点

  • 成人诊断可纳入抗苗勒管激素(AMH)水平替代超声检查。
  • 应识别代谢风险、心血管疾病、睡眠呼吸暂停及心理特征等高 prevalence 问题。
  • 强调健康生活方式、情绪健康与生活质量,并注意体重污名。

核心结论

  • 2023年国际循证指南基于最佳可得证据、多学科专家意见和患者偏好,为多囊卵巢综合征的评估与管理提供了明确的最佳实践建议。

研究设计与样本

  • 指南更新重新召集2018年网络,覆盖39个专业与患者组织、71个国家,召开20次会议和5次面对面论坛,处理58个优先临床问题,包括52项系统综述和3项叙述性综述。

主要发现

  • 技术证据报告约6000页,支撑77条循证推荐、54条共识推荐和123条实践要点。
  • 关键更新包括:细化个体诊断标准、简化诊断流程,并仅在成人中纳入AMH水平作为超声的替代。
  • 强化识别PCOS的更广泛特征,包括代谢风险因素、心血管疾病、睡眠呼吸暂停、心理特征高患病率及妊娠期不良结局高风险。
  • 强调疾病负担的多样性、医疗专业教育、循证患者信息、改进照护模式与共享决策。
  • 维持对健康生活方式、情绪健康和质量的重视,并关注体重污名。

关键数值与推荐

  • 指南包含254条推荐和实践要点,其中77条为循证推荐、54条为共识推荐、123条为实践要点。
  • 在成人中,AMH水平可作为超声检查的替代用于诊断。

临床怎么用

  • 临床医生应基于最佳可得证据、多学科专家意见和患者偏好,为PCOS患者提供一致、循证的照护。
  • 应识别并管理PCOS相关的代谢风险、心血管疾病、睡眠呼吸暂停、心理特征及妊娠期高风险。
  • 应重视健康生活方式、情绪健康和生活质量,并注意体重污名。
  • 应优先采用循证药物治疗和更廉价、更安全的生育管理。

局限性

  • 总体推荐虽得到加强、证据有所改善,但证据质量仍普遍为低至中等。
  • 在这一被忽视但常见的疾病中,目前迫切需要显著更多的研究。
  • 指南考虑并承认了区域卫生系统的差异,并提供了指南和翻译资源进一步适应的流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? SUMMARY ANSWER: International evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. WHAT IS KNOWN ALREADY: The 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from six continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low to low quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, evidence quality was low and evidence-practice gaps persist. STUDY DESIGN, SIZE, DURATION: The 2023 International Evidence-based Guideline update reengaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength and diversity and inclusion were considered throughout. PARTICIPANTS/ MATERIALS, SETTING, METHODS: This summary should be read in conjunction with the full Guideline for detailed participants and methods. Governance included a six-continent international advisory and management committee, five guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health and other experts, alongside consumers, project management, evidence synthesis, statisticians and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and five face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across five guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council (NHMRC). MAIN RESULTS AND THE ROLE OF CHANCE: The evidence in the assessment and management of PCOS has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include: i) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone (AMH) levels as an alternative to ultrasound in adults only; ii) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; iii) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care and shared decision making to improve patient experience, alongside greater research; iv) maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and v) emphasizing evidence-based medical therapy and cheaper and safer fertility management. LIMITATIONS, REASONS FOR CAUTION: Overall, recommendations are strengthened and evidence is improved, but remain generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. WIDER IMPLICATIONS OF THE FINDINGS: The 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation programme supports the Guideline with an integrated evaluation program. STUDY FUNDING/COMPETING INTEREST(S): This effort was primarily funded by the Australian Government via the National Health Medical Research Council (NHMRC) (APP1171592), supported by a partnership with American Society for Reproductive Medicine, Endocrine Society, European Society for Human Reproduction and Embryology, and the Society for Endocrinology. The Commonwealth Government of Australia also supported Guideline translation through the Medical Research Future Fund (MRFCRI000266). HJT and AM are funded by NHMRC fellowships. JT is funded by a Royal Australasian College of Physicians (RACP) fellowship. Guideline development group members were volunteers. Travel expenses were covered by the sponsoring organizations. Disclosures of interest were strictly managed according to NHMRC policy and are available with the full guideline, technical evidence report, peer review and responses (www.monash.edu/medicine/mchri/pcos). Of named authors HJT, CTT, AD, LM, LR, JBoyle, AM have no conflicts of interest to declare. JL declares grant from Ferring and Merck; consulting fees from Ferring and Titus Health Care; speaker's fees from Ferring; unpaid consultancy for Ferring, Roche Diagnostics and Ansh Labs; and sits on advisory boards for Ferring, Roche Diagnostics, Ansh Labs, and Gedeon Richter. TP declares a grant from Roche; consulting fees from Gedeon Richter and Organon; speaker's fees from Gedeon Richter and Exeltis; travel support from Gedeon Richter and Exeltis; unpaid consultancy for Roche Diagnostics; and sits on advisory boards for Roche Diagnostics. MC declares travels support from Merck; and sits on an advisory board for Merck. JBoivin declares grants from Merck Serono Ltd.; consulting fees from Ferring B.V; speaker's fees from Ferring Arzneimittell GmbH; travel support from Organon; and sits on an advisory board for the Office of Health Economics. RJN has received speaker's fees from Merck and sits on an advisory board for Ferring. AJoham has received speaker's fees from Novo Nordisk and Boehringer Ingelheim. The guideline was peer reviewed by special interest groups across our 39 partner and collaborating organizations, was independently methodologically assessed against AGREEII criteria and was approved by all members of the guideline development groups and by the NHMRC.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023. PMID: 37589624. doi:10.1016/j.fertnstert.2023.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。